Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC

Soohyun Lee, Jae Seon Lee, Jinho Seo, Seon Hyeong Lee, Joon Hee Kang, Jaewhan Song, Soo Youl Kim

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Anticancer drug resistance is a major challenge of cancer therapy. We found that irinotecan-resistant NSCLC cells showed increased mitochondrial oxidative phosphorylation compared to the drug sensitive NSCLC cells. Previously, we found that combined inhibition of aldehyde dehydrogenase using gossypol, and mitochondrial complex I using phenformin, effectively reduced oxidative phosphorylation in NSCLC. Here, we showed that targeting oxidative phosphorylation with gossypol and phenformin abrogated irinotecan resistance in NSCLC. Furthermore, irinotecan treatment by blocking oxidative phosphorylation induced synergistic anti-cancer effect in NSCLC. The pre-clinical xenograft model of human NSCLC also demonstrated a therapeutic response to the dual targeting treatment. Therefore, this combination of gossypol and phenformin increases irinotecan sensitivity as well as preventing irinotecan resistance.

Original languageEnglish
Article number15707
JournalScientific reports
Issue number1
Publication statusPublished - 2018 Dec 1

Bibliographical note

Publisher Copyright:
© 2018, The Author(s).

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC'. Together they form a unique fingerprint.

Cite this